{"abstract": "Novartis has obtained the rights to an anticlotting drug that could eventually compete with Plavix, the world\u2019s second-best-selling medicine.", "web_url": "https://www.nytimes.com/2009/02/12/health/12portola.html", "snippet": "Novartis has obtained the rights to an anticlotting drug that could eventually compete with Plavix, the world\u2019s second-best-selling medicine.", "lead_paragraph": "Novartis has obtained the worldwide rights to an anticlotting drug that could eventually compete with Plavix, the world\u2019s second-best-selling medicine behind the cholesterol pill Lipitor. ", "print_section": "B", "print_page": "7", "source": "The New York Times", "multimedia": [], "headline": {"main": "Novartis Buys Rights to a Drug to Thin Blood", "kicker": null, "content_kicker": null, "print_headline": "Novartis Buys Rights To a Drug To Thin Blood", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Plavix (Drug)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Medicine and Health", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Novartis A.G", "rank": 4, "major": "N"}], "pub_date": "2009-02-12T05:22:02+0000", "document_type": "article", "news_desk": "Business", "section_name": "Health", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/fdd4d428-7688-5d34-a518-2b36981d4801", "word_count": 347, "uri": "nyt://article/fdd4d428-7688-5d34-a518-2b36981d4801"}